Cyclodextrin Composition for Poorly Soluble Drug Solubility

The patent modifies the cyclodextrin molecule by introducing hydrophilic groups (such as carboxyl, hydroxyl, or amino groups) at specific positions on the cyclodextrin structure. This changes the chemical parameters of the cyclodextrin to improve its interaction with poorly soluble drugs, enhancing the inclusion effect and solubility enhancement capability.

The patent creates a composite system by combining cyclodextrin with hydrophilic modifying groups and potentially other adjuvants to form a modified cyclodextrin composition. This composite structure leverages the cavity inclusion capability of cyclodextrin while adding the solubility-enhancing properties of hydrophilic groups.

By chemically modifying cyclodextrin with hydrophilic groups, the patent changes the pharmacological parameters of the excipient to reduce its toxic effects at high doses while maintaining its solubility enhancement capability. This allows effective drug loading at lower cyclodextrin concentrations.

The modified cyclodextrin composition acts as a temporary solubility enhancer that facilitates drug delivery and then is metabolized or excreted, avoiding long-term accumulation and chronic toxicity. The hydrophilic modification enhances its biodegradability and reduces persistent harmful effects.

The patent introduces hydrophilic groups at specific local positions on the cyclodextrin molecule, creating regions of enhanced polarity that favor drug interaction. This localized modification allows the rest of the cyclodextrin structure to maintain its stable hydrogen-bonded network while the modified regions facilitate drug cavity insertion.

By changing the chemical parameters of cyclodextrin through hydrophilic group introduction, the patent alters the intermolecular interaction characteristics. This modifies the balance between structural stability and drug insertion capability, allowing both to coexist at optimal levels.